ArticleImmunoHorizons2025
Characterization of IgE cross-reactivity and allergenicity of peanut allergens.
Article in ImmunoHorizons, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
IgE cross-reactivity among peanut allergens is controversial, and allergenicity of peanut allergens other than Arachis hypogaea 2 [Ara h 2] remains to be elucidated. We investigated the origins of peanut IgE cross-reactivity using Western blotting, and allergenicity of peanut allergens employing a passive cutaneous anaphylaxis model. Peanut allergic IgE bound to a large swath of peanut proteins including Ara h 2, Ara h 1, Ara h 3, and Ara h 6. IgE cross-reactivity among peanut allergens could be inhibited by recombinant Ara h 2. Affinity-purified Ara h 2 IgE reconstituted broad IgE binding patterns to Ara h 1, Ara h 3, and Ara h 6 in addition to Ara h 2. Monoclonal human IgE and mouse IgG against peanut allergen component variably bound to other peanut allergen components. Ara h 2 and Ara h 6 could trigger Ara h 2 IgE-mediated peanut allergic reactivity, whereas Ara h 1 and Ara h 3 failed to do so. Ara h 1 IgE was incapable of mediating Ara h 1-triggered allergic reaction. These results revealed that Ara h 2 IgE was the origin of IgE cross-reactivity, and Ara h 2 IgE-mediated peanut allergic reactivity triggered by Ara h 2 and Ara h 6. Ara h 1 and Ara h 3 did not display detectable allergenicity. These results indicated that Ara h 2 IgE appeared to be the "master" responsible for IgE cross-reactivity among peanut allergens and might be the only IgE responsible for allergic reactivity in peanut allergy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.